Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06256068
Other study ID # KB/54/A2023
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date February 5, 2024
Est. completion date June 30, 2026

Study information

Verified date February 2024
Source Medical University of Warsaw
Contact Julia Haponiuk-Skwarlinska, MD
Phone 515400472
Email julia.haponiuk-skwarlinska@wum.edu.pl
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Cancer treatment in children is very effective, but unfortunately has side effects - unwanted, bad impact. Some drugs that are given during cancer treatment, in addition to their good effect, can affect the heart badly and can lower the physical activity tolerance, such as climbing stairs, fast walking, running, exercise. Physical activity is very important for the proper growth and development of children and future adults. Heart is an important organ pumping the blood around the body and its good function is one of the key determinants of physical activity level in humans. The goal of this study is to is to find what impacts physical activity level in children treated for cancer with treatment methods that may be toxic to the heart to learn about influence of this treatment on the physical activity level of these children. The main questions this study aims to answer are: - Do children after cancer treatment involving heart toxic treatment methods present lower level of daily physical activity in comparison to the children treated with different methods? - Is the level of physical activity related to the heart toxic treatment, or other such as exercise capacity (measured physical strength on the treadmill or standing bike), quality of life, lifestyle, social and demographic factors, body type as well as the knowledge about positive impact of physical activity, efficacy, and motivation to physical activity? Participants will: - fill in the questionnaire, - perform an exercise test on the treadmill or standing bike (to measure exercise capacity), - perform ALPHA test (physical fitness test) consisting of some simple exercise like jumping, running etc., - be measured and weighted, - be measured by the hand-grip test with the hand dynamometer machine, - wear activity-tracker band for 14 days, - be examined by the ultrasound of the heart (echocardiography). Researchers will compare 144 children treated with heart toxic methods for cancer to 144 children treated for cancer with non-toxic methods. The children will be aged 8-18 years old and will be 1-5 years after treatment for cancer. The researchers believe that finding what influences physical activity level in children after cancer treatment with heart toxic methods may - make the therapy for cancer in children better, with less side effects - by that, can cause increase in the physical activity and ensure better growth and health for these children in the future.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 290
Est. completion date June 30, 2026
Est. primary completion date June 30, 2026
Accepts healthy volunteers No
Gender All
Age group 8 Years to 18 Years
Eligibility Inclusion Criteria: Study group: - age 8-18 years, - diagnosis and completed treatment for cancer >1 year and <5 years ago, - remission of the cancer, - treatment involving use of anthracyclines, kinase inhibitors targeting BRC-ABL, hae-mopoietic stem cell transplantation and radiotherapy (TBI or mediastinum irradiation), - at least 6 weeks from the last signs or symptoms of an infection, - written consent signed by the parents and patients aged =16 years. Control group: - the same as for the experimental group and, - cancer treatment without use of anthracyclines, kinase inhibitors targeting BRC-ABL, haemopoietic stem cell transplantation and radiotherapy (TBI or mediastinum irradiation). Exclusion Criteria: - past history of cancer and its treatment with or without the use of anthracyclines, kinase inhibitors targeting BRC-ABL, haemopoietic stem cell transplantation and radiotherapy (TBI or mediastinum irradiation), - acute infection, - active acute inflammatory disease including: autoimmunological, neurological, pul-monological, endocrinological, cardiovascular, gastrointestinal, - platelet count < 20 G/L, - hemoglobin concentration < 9g /dL, - severe residual changes (protein loss syndrome, peritoneal, pericardial or pleural effu-sion, arrhythmia, metabolic disorders), - previously diagnosed congenital heart defects or other heart diseases (including cardi-omyopathy, heart failure, arrythmia), - relapse of the cancer at the moment of the enrollment to the study, - severe malnutrition <3 SD BMI weight-for-age, - lack of consent, - lack of patient cooperation. Additional exclusion criteria to conduct cardiopulmonary exercise test (CPET): - contraindications to CPET examination including chronic cardiovascular diseases or musculoskeletal system disorders, - excessive malaise (1 year after the treatment for the study group and the control group 1), - intellectual disability, - musculoskeletal system impairment, - chronic concomitant diseases, especially endocrinological, neurological, gastroin-testinal, pulmonological, - lack of cooperation during the CPET.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Medical University of Warsaw

Outcome

Type Measure Description Time frame Safety issue
Primary Physical activity level measured by the accelerometer Physical activity level measured by the accelerometer and the assessment of the WHO pediatric, age-adjusted physical activity norms achievement 14 days measurement for 1 individual
Secondary Percentage of participants disqualified from CPET Percentage of participants disqualified from cardio-pulmonary exercise test (CPET) examination - objective assessment of exercise capacity Measured at the enrollment
Secondary Exercise capacity measured in CPET VO2max below 47mL/kg/min for boys and 42 mL/kg/min for girls will be defined as the exercise capacity alterations in cardio-pulmonary exercise test Measured at the enrollment
Secondary Physical function in the ALPHA test battery defining of the physical function level as low, moderate or high according to the ALPHA test battery Measured at the enrollment
Secondary Cardiac function GLS (Global longitudinal strain) below average for age as well as the normal systolic function will be defined as a LVDd (Left ventricle diastolic diameter) within the normal limit and EF (ejection fraction) 55% or more, as well as the comparison to the control group Measured at the enrollment
See also
  Status Clinical Trial Phase
Completed NCT03826043 - THrombo-Embolic Event in Onco-hematology N/A
Terminated NCT03166631 - A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread Phase 1
Completed NCT01938846 - BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors Phase 1
Recruiting NCT06058312 - Individual Food Preferences for the Mediterranean Diet in Cancer Patients N/A
Completed NCT03308942 - Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants Phase 2
Recruiting NCT06018311 - Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads N/A
Withdrawn NCT05431439 - Omics of Cancer: OncoGenomics
Completed NCT01343043 - A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma Phase 1
Completed NCT01938638 - Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer Phase 1
Recruiting NCT05514444 - Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001) Phase 1
Recruiting NCT02292641 - Beyond TME Origins N/A
Terminated NCT00954512 - Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004) Phase 1/Phase 2
Recruiting NCT04958239 - A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) Phase 1
Recruiting NCT04627376 - Multimodal Program for Cancer Related Cachexia Prevention N/A
Completed NCT01222728 - Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
Recruiting NCT06004440 - Real World Registry for Use of the Ion Endoluminal System
Active, not recruiting NCT05636696 - COMPANION: A Couple Intervention Targeting Cancer-related Fatigue N/A
Not yet recruiting NCT06035549 - Resilience in East Asian Immigrants for Advance Care Planning Discussions N/A
Recruiting NCT06004466 - Noninvasive Internal Jugular Venous Oximetry
Completed NCT02909348 - Immunophenotyping of Melanoma Patients on Treatment With Pembrolizumab